Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines

Aloysious Ssemaganda; Ashwini Kumar Giddam; Mehfuz Zaman; Mariusz Skwarczynski; Istvan Toth; Danielle I Stanisic; Michael F Good

doi:10.3389/fimmu.2019.00135

Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines

Front Immunol. 2019 Feb 1:10:135. doi: 10.3389/fimmu.2019.00135. eCollection 2019.

Authors

Aloysious Ssemaganda¹, Ashwini Kumar Giddam¹, Mehfuz Zaman¹, Mariusz Skwarczynski², Istvan Toth^{2

3

4}, Danielle I Stanisic¹, Michael F Good¹

Affiliations

¹ Institute for Glycomics, Griffith University, Southport, QLD, Australia.
² School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia.
³ School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
⁴ Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.

Abstract

In the development of vaccines, the ability to initiate both innate and subsequent adaptive immune responses need to be considered. Live attenuated vaccines achieve this naturally, while inactivated and sub-unit vaccines generally require additional help provided through delivery systems and/or adjuvants. Liposomes present an attractive adjuvant/delivery system for antigens. Here, we review the key aspects of immunity against Plasmodium parasites, liposome design considerations and their current application in the development of a malaria vaccine.

Trial registration: ClinicalTrials.gov NCT02905019.

Keywords: Plasmodium; adjuvant; immunity; liposomes; malaria; vaccine.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Liposomes
Malaria Vaccines / administration & dosage*
Plasmodium / immunology*

Substances

Liposomes
Malaria Vaccines

Associated data

ClinicalTrials.gov/NCT02905019